Latest news
Hansoh Pharmaceutical Receives NMPA Approval for Clinical Trials of HS-10582 Tablets for Hypercholesterolemia and Dyslipidemia 1 – Minichart - MinichartMinichart · Fri, 07 Aug 2026 04:24:00 GMTAvere Therapeutics - The Pharma LetterThe Pharma Letter · Mon, 03 Aug 2026 15:34:12 GMTHansoh Pharmaceutical Group Company Limited Revenue Breakdown – HKEX:3692 - TradingViewTradingView · Fri, 31 Jul 2026 15:42:45 GMTStories of High-Quality Development | Biopharmaceuticals: From following to leading - People's Daily OnlinePeople's Daily Online · Fri, 31 Jul 2026 06:42:00 GMTGSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China - GSKGSK · Tue, 28 Jul 2026 07:00:00 GMTCLSA Sticks to Their Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692) - The Globe and MailThe Globe and Mail · Tue, 28 Jul 2026 07:00:00 GMTGSK, Hansoh's bone cancer drug meets main goal in late-stage trial - ReutersReuters · Tue, 28 Jul 2026 07:00:00 GMTGSK's Bone Cancer Drug Meets Primary Endpoint in Late-stage China Study - MoomooMoomoo · Tue, 28 Jul 2026 07:00:00 GMT